Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLEXERIL vs AMITRIPTYLINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.
Inhibits reuptake of serotonin and norepinephrine, leading to increased concentrations at synaptic cleft; also blocks histamine H1, alpha-1 adrenergic, and muscarinic cholinergic receptors.
Adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions (FDA-approved),Off-label: Fibromyalgia, chronic muscle spasm, tension headaches, and as a sleep aid
Major depressive disorder,Neuropathic pain,Fibromyalgia,Migraine prophylaxis,Chronic tension-type headache,Insomnia (off-label),Irritable bowel syndrome (off-label)
10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.
Oral: 25-150 mg daily in divided doses or as a single bedtime dose; maximum 300 mg/day.
Terminal elimination half-life is 18 hours (range 8–37 hours) with clinical context: requires dose adjustment in hepatic impairment; steady-state reached in ~3–5 days.
Terminal elimination half-life is 15-35 hours (range 9-46 hours); clinical context: steady-state concentrations achieved within 7-10 days; may be prolonged in elderly, hepatic impairment, or CYP2D6 poor metabolizers.
Primarily hepatic via CYP3A4, CYP1A2, and CYP2D6; undergoes N-demethylation and glucuronidation. Active metabolite: norcyclobenzaprine.
Primarily hepatic via CYP2D6, CYP3A4, CYP1A2, and CYP2C19; active metabolite nortriptyline; undergoes demethylation, hydroxylation, and conjugation.
Primarily hepatic; approximately 50% excreted in urine as metabolites, less than 1% unchanged; 40% excreted in feces via bile.
Primarily renal (approximately 30-50% as unchanged drug and metabolites, mainly glucuronide conjugates and hydroxylated metabolites). Fecal excretion accounts for <5%. Enterohepatic recirculation may occur.
~93% bound to plasma proteins, primarily albumin.
Approximately 94-96%; primarily bound to alpha-1-acid glycoprotein (AAG), with minor binding to albumin and lipoproteins.
~14 L/kg (range 10–20 L/kg), indicating extensive tissue distribution.
10-20 L/kg (large Vd due to extensive tissue binding); clinical meaning: high tissue penetration, especially CNS, and slow redistribution from tissues.
Oral: ~33% due to extensive first-pass metabolism.
Oral: 30-60% due to extensive first-pass metabolism (CYP2C19, CYP3A4, CYP2D6); significant interindividual variability.
No specific dosage adjustment guidelines; use with caution in renal impairment due to potential for increased side effects.
GFR 10-50 m L/min: use 50% of normal dose; GFR <10 m L/min: use 25% of normal dose.
Contraindicated in hepatic impairment; Child-Pugh class A, B, C: no safe dosage established.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Not recommended for use in children under 15 years old; safety and efficacy not established.
Adolescents: 10-50 mg daily in divided doses; children under 12 years (for enuresis): 6-10 years: 10-20 mg, 11+ years: 25-50 mg at bedtime.
Use lower starting dose (e.g., 5 mg) and titrate slowly; increased risk of sedation and anticholinergic effects. May not be well tolerated; consider alternative therapy.
Start at 10-25 mg at bedtime; increase by 10-25 mg every 3-7 days as tolerated; maximum 75-100 mg daily; monitor for CNS and anticholinergic effects.
None
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. Close monitoring for clinical worsening, suicidality, or unusual changes in behavior is recommended.
Should not be used for longer than 2-3 weeks (acute use only),May impair mental or physical abilities required for driving or operating machinery,Central nervous system depression additive with alcohol and other CNS depressants,Anticholinergic effects: caution in patients with angle-closure glaucoma, urinary retention, or prostatic hypertrophy,Cardiovascular effects: risk of arrhythmias, especially in patients with preexisting cardiac disease (tachycardia, QT prolongation),Serotonin syndrome risk when used with MAOIs, SSRIs, SNRIs, or other serotonergic drugs,Hepatic impairment: lower doses recommended
Cardiotoxicity (QT prolongation, arrhythmias), serotonin syndrome, activation of mania/hypomania, angle-closure glaucoma, urinary retention, seizures, increased intraocular pressure, orthostatic hypotension, drowsiness, withdrawal symptoms upon abrupt discontinuation.
Concurrent use of MAOIs or within 14 days of MAOI therapy,Acute recovery phase of myocardial infarction,Arrhythmias, heart block, or congestive heart failure,Hyperthyroidism
Concurrent use with MAOIs (risk of serotonin syndrome), recent myocardial infarction, hypersensitivity to tricyclic antidepressants, during acute recovery phase of MI, use with cisapride or other QT-prolonging drugs.
Alcohol should be avoided due to additive CNS depression. No specific food interactions; take with or without food. Grapefruit juice does not significantly interact, but caution with high-fat meals may alter absorption slightly.
Avoid alcohol and tyramine-rich foods (e.g., aged cheese, cured meats, soy sauce) due to risk of hypertensive crisis. Limit caffeine intake; may increase CNS stimulation. Grapefruit juice may increase plasma levels; avoid or limit consumption.
Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. Second trimester: no known risk. Third trimester: potential for neonatal adverse effects such as respiratory depression and withdrawal if used near term.
First trimester: Limited data suggest a small increased risk of congenital malformations, particularly cardiovascular defects. Second trimester: No specific malformation risk, but possible effects on fetal growth. Third trimester: Risk of neonatal withdrawal syndrome (irritability, feeding difficulties) and anticholinergic effects (constipation, urinary retention). Overall risk is low; benefits may outweigh risks in severe depression.
Excreted in breast milk in small amounts (M/P ratio not established). Clinical relevance uncertain; however, due to potential for adverse effects in nursing infants, caution is advised. Alternative therapies preferred, especially when nursing a premature or low-birth-weight infant.
Amitriptyline and its metabolite nortriptyline are excreted in breast milk with an M/P ratio of approximately 1.0 for amitriptyline. Infant daily dose is about 1-2% of maternal weight-adjusted dose. No adverse effects reported in most infants; however, monitor for drowsiness, poor feeding. American Academy of Pediatrics considers amitriptyline compatible with breastfeeding.
No specific dosing adjustments recommended for pregnancy. Use lowest effective dose and shortest duration due to potential neonatal effects. Pharmacokinetics may be altered in pregnancy; however, no dose adjustment guidelines exist.
Pregnancy increases clearance of amitriptyline by 30-50% due to expanded plasma volume and enhanced hepatic metabolism. Serum levels may decrease, potentially requiring dose increase of 30-50% to maintain efficacy. Consider therapeutic drug monitoring (target trough 100-250 ng/m L) for dose titration. Postpartum dosing should be reduced to prepregnancy levels.
Flexeril (cyclobenzaprine) is structurally related to tricyclic antidepressants (TCAs) and shares similar anticholinergic and sedative properties. It should not be used longer than 2-3 weeks due to lack of evidence for efficacy beyond that duration. Avoid in patients with hyperthyroidism, heart block, or recent MI. Concomitant use with MAOIs can cause hypertensive crisis. Onset of muscle relaxation is delayed; therapeutic effect may not be apparent until after 2-4 days. Sedation is the most common side effect and can be used to aid sleep.
Do not discontinue abruptly; taper over 2-4 weeks to prevent withdrawal symptoms. Use with caution in patients with cardiac conduction defects (prolongs QTc interval). Serum levels >500 ng/m L are associated with toxicity. Start at 10-25 mg at bedtime for neuropathic pain. May precipitate mania in bipolar disorder.
Do not take for longer than 3 weeks unless directed by your doctor.,This medication may cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase sedation.,Do not stop suddenly if taken regularly; taper dose to avoid withdrawal symptoms like headache or nausea.,Inform your doctor if you have glaucoma, urinary retention, or are taking MAO inhibitors (e.g., phenelzine, tranylcypromine).,Take exactly as prescribed; do not increase dose or frequency.,May cause dry mouth; use sugar-free gum or candy for relief.
Take at bedtime to minimize daytime sedation.,Avoid alcohol and other CNS depressants.,Report symptoms of urinary retention, vision changes, or rapid heartbeat.,May cause dry mouth; use sugar-free gum or candy.,Avoid abrupt discontinuation; follow your doctor's tapering plan.,Notify your doctor if you experience suicidal thoughts or worsening depression.
No interactions on record
"Amitriptyline, a tricyclic antidepressant, may inhibit the metabolism of captopril, an ACE inhibitor, leading to increased serum concentrations of captopril. This elevation can potentiate captopril's antihypertensive effects and increase the risk of adverse effects such as hypotension, renal impairment, and hyperkalemia. Patients should be monitored closely for signs of exaggerated hypotensive response and electrolyte disturbances."
"Rifapentine, a potent inducer of cytochrome P450 (CYP) enzymes, specifically CYP3A4 and CYP2C19, significantly increases the hepatic metabolism of amitriptyline, a tricyclic antidepressant primarily metabolized by CYP2C19 and CYP3A4. This induction leads to markedly reduced plasma concentrations of amitriptyline and its active metabolite nortriptyline, potentially resulting in loss of antidepressant efficacy or relapse of depressive symptoms. Additionally, abrupt withdrawal of rifapentine without dose adjustment of amitriptyline may cause increased tricyclic levels and toxicity."
"Dapiprazole, an alpha-1 adrenergic receptor antagonist, and amitriptyline, a tricyclic antidepressant with significant anticholinergic properties, can have additive anticholinergic and sympatholytic effects when coadministered. This may lead to enhanced central nervous system depression, hypotension, urinary retention, and constipation. Patients should be monitored for excessive sedation, orthostatic hypotension, and anticholinergic toxicity."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLEXERIL vs AMITRIPTYLINE HYDROCHLORIDE, answered by our medical review team.
FLEXERIL is a Muscle Relaxant that works by Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.. AMITRIPTYLINE HYDROCHLORIDE is a Tricyclic Antidepressant that works by Inhibits reuptake of serotonin and norepinephrine, leading to increased concentrations at synaptic cleft; also blocks histamine H1, alpha-1 adrenergic, and muscarinic cholinergic receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLEXERIL and AMITRIPTYLINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLEXERIL is: 10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.. The standard adult dose of AMITRIPTYLINE HYDROCHLORIDE is: Oral: 25-150 mg daily in divided doses or as a single bedtime dose; maximum 300 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLEXERIL and AMITRIPTYLINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLEXERIL is classified as Category C. Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. . AMITRIPTYLINE HYDROCHLORIDE is classified as Category C. First trimester: Limited data suggest a small increased risk of congenital malformations, particularly cardiovascular defects. Second trimester: No specific malformation risk, but . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.